Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Current Deferred Revenue (2022 - 2025)

Goldenwell Biotech filings provide 4 years of Current Deferred Revenue readings, the most recent being $37500.0 for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 3030.22% to $37500.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $37500.0, a 3030.22% increase, with the full-year FY2024 number at $1860.0, down 2.82% from a year prior.
  • Current Deferred Revenue hit $37500.0 in Q3 2025 for Goldenwell Biotech, down from $62500.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $62500.0 in Q2 2025 to a low of $1198.0 in Q1 2024.
  • Median Current Deferred Revenue over the past 4 years was $1410.0 (2022), compared with a mean of $9572.3.
  • Biggest five-year swings in Current Deferred Revenue: fell 15.04% in 2024 and later surged 5117.03% in 2025.
  • Goldenwell Biotech's Current Deferred Revenue stood at $1410.0 in 2022, then surged by 35.74% to $1914.0 in 2023, then dropped by 2.82% to $1860.0 in 2024, then soared by 1916.13% to $37500.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $37500.0 (Q3 2025), $62500.0 (Q2 2025), and $1860.0 (Q1 2025) per Business Quant data.